PT - JOURNAL ARTICLE AU - Kouriba, B AU - Dürr, A AU - Rehn, A AU - Sangaré, AK AU - Traoré, BY AU - Bestehorn-Willmann, MS AU - Ouedraogo, WLJ AU - Heitzer, A AU - Sogodogo, E AU - Maiga, A AU - Walter, MC AU - Zimmermann, F AU - Wölfel, R AU - Antwerpen, MH TI - First phylogenetic analysis of Malian SARS-CoV-2 sequences provide molecular insights into the genomic diversity of the Sahel region AID - 10.1101/2020.09.23.20165639 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.23.20165639 4099 - http://medrxiv.org/content/early/2020/09/25/2020.09.23.20165639.1.short 4100 - http://medrxiv.org/content/early/2020/09/25/2020.09.23.20165639.1.full AB - We are currently facing a pandemic of COVID-19, caused by a spillover from an animal-originating coronavirus to humans occuring in the Wuhan region, China, in December 2019. From China the virus has spread to 188 countries and regions worldwide, reaching the Sahel region on the 2nd of March 2020. Since whole genome sequencing (WGS) data is very crucial to understand the spreading dynamics of the ongoing pandemic, but only limited sequence data is available from the Sahel region to date, we have focused our efforts on generating the first Malian sequencing data available. Screening of 217 Malian patient samples for the presence of SARS-CoV-2 resulted in 38 positive isolates from which 21 whole genome sequences were generated. Our analysis shows that both, the early A (19B) and the fast evolving B (20A/C) clade, are present in Mali indicating multiple and independent introductions of the SARS-CoV-2 to the Sahel region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Enable and Enhance Initiative of the German Government Security cooperation on biological threats in Mali and G5-Sahel (Ertuechtigungsinitiative der Deutschen Bundesregierung, OR12-370.43 ERT MLI/G5S) and Fondation Merieux, Lyon, France. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of residual clinical specimens in this study was in accordance with the statement of the Central Ethics Committee of the German Medical Association on the further use of human body materials for the purposes of medical research of February 20, 2003. In addition, this study was approved by the Comite d'Ethique des Faculte de Medicine/d'Odontostomatologie et de Pharmacie (FMOS/FAPH) of the Universite des Science, des Techiques et de Technologies de Bamako (No 2020/201/CE/FMOS/FAPH, 17 September 2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomes are available at gisaid.org